Losartan Activates Brown Fat via Distinct Pathways, Linking Metabolic Health to Mental Well-Being

3 min read
Source: ScienceDaily
Losartan Activates Brown Fat via Distinct Pathways, Linking Metabolic Health to Mental Well-Being
Photo: ScienceDaily
TL;DR

A new study in Nature reveals that losartan, a common blood pressure medication, can activate calorie-burning brown fat through mechanisms separate from its antihypertensive effects. Researchers at Rockefeller University and Memorial Sloan Kettering Cancer Center analyzed over 100,000 patient scans, finding that detectable brown fat correlates with lower rates of heart disease, diabetes, anxiety, and depression. Mouse experiments confirmed that losartan increases metabolic activity without altering body weight, suggesting potential for repurposing the drug to treat metabolic disorders without affecting blood pressure.

Key points

  • Losartan, an angiotensin receptor blocker, was found to directly increase metabolic activity in brown fat cells through molecular pathways distinct from those regulating blood pressure.
  • Analysis of over 100,000 patient PET/CT scans showed that individuals with detectable brown fat had lower rates of anxiety, depression, coronary artery disease, and type II diabetes.
  • Brown fat activity in specific regions, such as the armpits, was linked to decreased risks of high blood pressure, while overall presence correlated with better glycemic and lipid profiles.
  • Mouse trials demonstrated that losartan increased energy expenditure and oxygen consumption without causing weight changes, supporting the potential for isolated metabolic benefits.
  • The study also noted that selective serotonin reuptake inhibitors (SSRIs) may suppress brown fat activity, and that brown fat presence was associated with higher rates of osteoporosis and certain skin diseases.

Background

This research expands on a 2021 study by Paul Cohen’s team, which analyzed approximately 50,000 patients and linked brown fat to lower cardiometabolic risks. The current study doubles the patient cohort and examines over 500 diagnostic codes, broadening the scope to include psychiatric conditions. It follows earlier findings in September 2026 regarding tirzepatide’s effects on brown fat and aligns with ongoing investigations into how metabolic health intersects with mental well-being.

Why it matters

The discovery that losartan activates brown fat through pathways independent of blood pressure regulation offers a potential avenue for developing therapies that improve metabolic health without causing hypotension. The link between brown fat and reduced psychiatric conditions suggests that metabolic interventions could have broader mental health benefits, though further research is needed to understand these associations and address potential trade-offs like increased osteoporosis risk.

What to watch

Researchers plan to investigate the genetics of individuals with high brown fat activity, explore the mechanisms behind the link between brown fat and lower rates of anxiety and depression, and evaluate other medications associated with brown fat activity. Future studies will aim to determine if the metabolic benefits of brown fat activation can be safely harnessed for therapeutic purposes.

Share this article

Want the full story? Read the original reporting

Read on ScienceDaily